698 related articles for article (PubMed ID: 8316295)
1. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1.
Brown JH; Jardetzky TS; Gorga JC; Stern LJ; Urban RG; Strominger JL; Wiley DC
Nature; 1993 Jul; 364(6432):33-9. PubMed ID: 8316295
[TBL] [Abstract][Full Text] [Related]
2. Exploration of the P6/P7 region of the peptide-binding site of the human class II major histocompatability complex protein HLA-DR1.
Zavala-Ruiz Z; Sundberg EJ; Stone JD; DeOliveira DB; Chan IC; Svendsen J; Mariuzza RA; Stern LJ
J Biol Chem; 2003 Nov; 278(45):44904-12. PubMed ID: 12952957
[TBL] [Abstract][Full Text] [Related]
3. A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens.
Zhu X; Bavari S; Ulrich R; Sadegh-Nasseri S; Ferrone S; McHugh L; Mage M
Eur J Immunol; 1997 Aug; 27(8):1933-41. PubMed ID: 9295029
[TBL] [Abstract][Full Text] [Related]
4. The class II MHC protein HLA-DR1 in complex with an endogenous peptide: implications for the structural basis of the specificity of peptide binding.
Murthy VL; Stern LJ
Structure; 1997 Oct; 5(10):1385-96. PubMed ID: 9351812
[TBL] [Abstract][Full Text] [Related]
5. Affinity maturation of human CD4 by yeast surface display and crystal structure of a CD4-HLA-DR1 complex.
Wang XX; Li Y; Yin Y; Mo M; Wang Q; Gao W; Wang L; Mariuzza RA
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15960-5. PubMed ID: 21900604
[TBL] [Abstract][Full Text] [Related]
6. N-terminal elongation of a peptide determinant beyond the first primary anchor improves binding to H-2 I-Ad and HLA-DR1 by backbone-dependent and aromatic side chain-dependent interactions, respectively.
Bartnes K; Leon F; Briand JP; Travers PJ; Hannestad K
Eur J Immunol; 1999 Jan; 29(1):189-95. PubMed ID: 9933100
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide.
Stern LJ; Brown JH; Jardetzky TS; Gorga JC; Urban RG; Strominger JL; Wiley DC
Nature; 1994 Mar; 368(6468):215-21. PubMed ID: 8145819
[TBL] [Abstract][Full Text] [Related]
8. Accuracy of a structural homology model for a class II histocompatibility protein, HLA-DR1: comparison to the crystal structure.
Nauss JL; Reid RH; Sadegh-Nasseri S
J Biomol Struct Dyn; 1995 Jun; 12(6):1213-33. PubMed ID: 7669268
[TBL] [Abstract][Full Text] [Related]
9. Dynamic flexibility of a peptide-binding groove of human HLA-DR1 class II MHC molecules: normal mode analysis of the antigen peptide-class II MHC complex.
Nojima H; Takeda-Shitaka M; Kurihara Y; Kamiya K; Umeyama H
Chem Pharm Bull (Tokyo); 2003 Aug; 51(8):923-8. PubMed ID: 12913229
[TBL] [Abstract][Full Text] [Related]
10. Disruption of hydrogen bonds between major histocompatibility complex class II and the peptide N-terminus is not sufficient to form a human leukocyte antigen-DM receptive state of major histocompatibility complex class II.
Schulze MS; Anders AK; Sethi DK; Call MJ
PLoS One; 2013; 8(7):e69228. PubMed ID: 23976922
[TBL] [Abstract][Full Text] [Related]
11. Zinc induces dimerization of the class II major histocompatibility complex molecule that leads to cooperative binding to a superantigen.
Li H; Zhao Y; Guo Y; Li Z; Eisele L; Mourad W
J Biol Chem; 2007 Mar; 282(9):5991-6000. PubMed ID: 17166841
[TBL] [Abstract][Full Text] [Related]
12. The N-terminal region of photocleavable peptides that bind HLA-DR1 determines the kinetics of fragment release.
Negroni MP; Stern LJ
PLoS One; 2018; 13(7):e0199704. PubMed ID: 29965980
[TBL] [Abstract][Full Text] [Related]
13. [The inhibitory effect of hyporesponsive peptide on human leukocyte antigen-DRbeta1 specific T cell activation].
Zhou Q; Cheng YJ; Li ZG; Zhou WH; Lu HS
Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(17):1505-9. PubMed ID: 14521731
[TBL] [Abstract][Full Text] [Related]
14. Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DR1.
Kim J; Urban RG; Strominger JL; Wiley DC
Science; 1994 Dec; 266(5192):1870-4. PubMed ID: 7997880
[TBL] [Abstract][Full Text] [Related]
15. Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides.
Jardetzky TS; Brown JH; Gorga JC; Stern LJ; Urban RG; Strominger JL; Wiley DC
Proc Natl Acad Sci U S A; 1996 Jan; 93(2):734-8. PubMed ID: 8570625
[TBL] [Abstract][Full Text] [Related]
16. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size.
Chicz RM; Urban RG; Lane WS; Gorga JC; Stern LJ; Vignali DA; Strominger JL
Nature; 1992 Aug; 358(6389):764-8. PubMed ID: 1380674
[TBL] [Abstract][Full Text] [Related]
17. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3.
Ghosh P; Amaya M; Mellins E; Wiley DC
Nature; 1995 Nov; 378(6556):457-62. PubMed ID: 7477400
[TBL] [Abstract][Full Text] [Related]
18. Identification of HLA-DR1 beta chain residues critical for binding staphylococcal enterotoxins A and E.
Karp DR; Long EO
J Exp Med; 1992 Feb; 175(2):415-24. PubMed ID: 1370684
[TBL] [Abstract][Full Text] [Related]
19. Peptide linkage to the α-subunit of MHCII creates a stably inverted antigen presentation complex.
Schlundt A; Günther S; Sticht J; Wieczorek M; Roske Y; Heinemann U; Freund C
J Mol Biol; 2012 Oct; 423(3):294-302. PubMed ID: 22820093
[TBL] [Abstract][Full Text] [Related]
20. Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum.
Busch R; Cloutier I; Sékaly RP; Hämmerling GJ
EMBO J; 1996 Jan; 15(2):418-28. PubMed ID: 8617217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
